Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming.

ABSTRACT:

Background

The Ad26.COV2.S vaccine, which was approved as a single-shot immunization regimen, has been shown to be effective against severe coronavirus disease 2019. However, this vaccine induces lower severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S)-specific antibody levels than those induced by messenger RNA (mRNA)-based vaccines. The immunogenicity and reactogenicity of a homologous or heterologous booster in persons who have received an Ad26.COV2.S priming dose are unclear.

Methods

In this single-blind, multicenter, randomized, controlled trial involving health care workers who had received a priming dose of Ad26.COV2.S vaccine, we assessed immunogenicity and reactogenicity 28 days after a homologous or heterologous booster vaccination. The

SUBMITTER: Sablerolles RSG 

PROVIDER: S-EPMC8796791 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature